Compare ITRN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRN | EVO |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | Israel | Germany |
| Employees | N/A | 4553 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 994.5M |
| IPO Year | 2005 | N/A |
| Metric | ITRN | EVO |
|---|---|---|
| Price | $57.18 | $2.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $60.67 | $7.00 |
| AVG Volume (30 Days) | ★ 120.9K | 29.8K |
| Earning Date | 05-26-2026 | 04-08-2026 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.38 | $1.37 |
| Revenue Next Year | $8.21 | $10.05 |
| P/E Ratio | $16.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.71 | $2.31 |
| 52 Week High | $68.30 | $4.42 |
| Indicator | ITRN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 57.27 |
| Support Level | $55.33 | $2.88 |
| Resistance Level | $62.31 | $3.30 |
| Average True Range (ATR) | 2.21 | 0.06 |
| MACD | -0.91 | 0.03 |
| Stochastic Oscillator | 3.21 | 91.89 |
Ituran Location and Control Ltd is a provider of location-based services. The company operates in two segments, namely Telematics services and Telematics products. The Telematics services segment consists of regionally-based stolen vehicle recovery (SVR) services, fleet management services, and value-added services comprised of personal locater services and concierge services. The Telematics product segment consists of short and medium-range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location and automatic vehicle identification. Its geographical segments include Israel, Brazil, and Others. The company derives maximum revenue from Israel.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.